Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2106 (LINC02106) is a long non-coding RNA (lncRNA) of the lincRNA subclass, meaning it is a transcript over 200 nucleotides in length that does not overlap with protein-coding genes and does not encode a protein[1][7]. Its functions are not specifically described in the current literature, and there is no direct association with disease roles, therapeutic targeting, biomarkers, or drug interactions based on available data. Like other lincRNAs, it may play a regulatory role in gene expression, chromatin organization, or interaction with RNA-binding proteins, although these are speculative generalizations for the class and not specific for LINC02106[1][5][7]. There is no evidence to suggest that LINC02106 is currently a therapeutic target or has an established role in pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2106 (LINC02106).